Aptose Biosciences Inc. (APS.TO)
CAD 0.27
(0.0%)
CAD 0.27
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.23 Million USD | 76.91% |
| 2022 | -35.66 Million USD | 7.45% |
| 2021 | -38.54 Million USD | 66.87% |
| 2020 | -116.31 Million USD | -48.54% |
| 2019 | -78.31 Million USD | -411.86% |
| 2018 | -15.29 Million USD | -43.91% |
| 2017 | -10.63 Million USD | -34.02% |
| 2016 | -7.93 Million USD | 4.31% |
| 2015 | -8.28 Million USD | 28.32% |
| 2014 | -11.56 Million USD | 33.39% |
| 2013 | -17.36 Million USD | -2640.36% |
| 2012 | -633.56 Thousand USD | -212.56% |
| 2011 | 562.84 Thousand USD | 160.35% |
| 2010 | -932.58 Thousand USD | -395.49% |
| 2009 | 315.6 Thousand USD | -96.21% |
| 2008 | 8.32 Million USD | -17.96% |
| 2007 | 10.14 Million USD | 3.04% |
| 2006 | 9.84 Million USD | 30.49% |
| 2005 | 7.54 Million USD | 27.37% |
| 2004 | 5.92 Million USD | 853.44% |
| 2003 | -786.46 Thousand USD | -19.24% |
| 2002 | -659.55 Thousand USD | 13.5% |
| 2001 | -762.46 Thousand USD | 57.87% |
| 2000 | -1.8 Million USD | 94.67% |
| 1999 | -33.98 Million USD | -3755.16% |
| 1998 | -881.66 Thousand USD | 1.21% |
| 1997 | -892.48 Thousand USD | 31.67% |
| 1996 | -1.3 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -6.42 Million USD | 21.97% |
| 2024 Q2 | -7.51 Million USD | -16.88% |
| 2023 Q3 | -14.61 Million USD | -103.03% |
| 2023 Q1 | -21.53 Million USD | 39.61% |
| 2023 Q2 | -7.19 Million USD | 66.59% |
| 2023 Q4 | -8.23 Million USD | 43.62% |
| 2023 FY | -8.23 Million USD | 76.91% |
| 2022 Q2 | -39.63 Million USD | -8.7% |
| 2022 Q1 | -36.46 Million USD | 5.39% |
| 2022 Q3 | -27.72 Million USD | 30.06% |
| 2022 Q4 | -35.66 Million USD | -28.67% |
| 2022 FY | -35.66 Million USD | 7.45% |
| 2021 Q2 | -82.51 Million USD | 4.2% |
| 2021 Q3 | -74.39 Million USD | 9.84% |
| 2021 Q4 | -38.54 Million USD | 48.2% |
| 2021 FY | -38.54 Million USD | 66.87% |
| 2021 Q1 | -86.13 Million USD | 25.95% |
| 2020 Q4 | -116.31 Million USD | -18.05% |
| 2020 Q3 | -98.53 Million USD | -86.59% |
| 2020 Q2 | -52.8 Million USD | 9.47% |
| 2020 Q1 | -58.33 Million USD | 25.51% |
| 2020 FY | -116.31 Million USD | -48.54% |
| 2019 Q3 | -19.04 Million USD | 24.38% |
| 2019 Q1 | -14.77 Million USD | 3.43% |
| 2019 Q4 | -78.31 Million USD | -311.1% |
| 2019 FY | -78.31 Million USD | -411.86% |
| 2019 Q2 | -25.19 Million USD | -70.5% |
| 2018 Q4 | -15.29 Million USD | -1.61% |
| 2018 Q2 | -17.94 Million USD | -16.46% |
| 2018 FY | -15.29 Million USD | -43.91% |
| 2018 Q1 | -15.4 Million USD | -44.93% |
| 2018 Q3 | -15.05 Million USD | 16.09% |
| 2017 Q4 | -10.63 Million USD | -33.79% |
| 2017 Q3 | -7.94 Million USD | -0.36% |
| 2017 Q2 | -7.91 Million USD | 11.7% |
| 2017 Q1 | -8.96 Million USD | -13.04% |
| 2017 FY | -10.63 Million USD | -34.02% |
| 2016 Q4 | -7.93 Million USD | -0.86% |
| 2016 Q1 | -5.19 Million USD | 37.34% |
| 2016 Q2 | -9.73 Million USD | -87.37% |
| 2016 FY | -7.93 Million USD | 4.31% |
| 2016 Q3 | -7.86 Million USD | 19.19% |
| 2015 Q4 | -8.28 Million USD | 26.53% |
| 2015 FY | -8.28 Million USD | 28.32% |
| 2015 Q1 | -9.74 Million USD | -84146.87% |
| 2015 Q2 | -13.5 Million USD | -38.59% |
| 2015 Q3 | -11.28 Million USD | 16.43% |
| 2014 Q2 | -17.36 Million USD | -240.22% |
| 2014 Q4 | -11.56 Thousand USD | 99.92% |
| 2014 Q1 | -5.1 Million USD | -2340.47% |
| 2014 FY | -11.56 Million USD | 33.39% |
| 2014 Q3 | -14.69 Million USD | 15.36% |
| 2013 Q3 | 227.66 Thousand USD | 135.93% |
| 2013 Q4 | -209.1 Thousand USD | -191.85% |
| 2013 Q1 | -1.51 Million USD | 46.52% |
| 2013 Q2 | -633.56 Thousand USD | 58.21% |
| 2013 FY | -17.36 Million USD | -2640.36% |
| 2012 Q3 | -4.17 Million USD | -841.05% |
| 2012 Q1 | 198.14 Thousand USD | 124.18% |
| 2012 Q4 | -2.83 Million USD | 32.03% |
| 2012 FY | -633.56 Thousand USD | -212.56% |
| 2012 Q2 | 562.84 Thousand USD | 184.06% |
| 2011 Q3 | -1.73 Million USD | -86.54% |
| 2011 FY | 562.84 Thousand USD | 160.35% |
| 2011 Q4 | -819.29 Thousand USD | 52.9% |
| 2011 Q2 | -932.58 Thousand USD | 50.57% |
| 2011 Q1 | -1.88 Million USD | -2.3% |
| 2010 Q1 | -844.82 Thousand USD | 63.53% |
| 2010 Q2 | 315.6 Thousand USD | 137.36% |
| 2010 Q4 | -1.84 Million USD | -253.6% |
| 2010 Q3 | 1.2 Million USD | 280.38% |
| 2010 FY | -932.58 Thousand USD | -395.49% |
| 2009 Q2 | 8.32 Million USD | 27.78% |
| 2009 Q3 | -790.68 Thousand USD | -109.5% |
| 2009 Q4 | -2.31 Million USD | -192.95% |
| 2009 FY | 315.6 Thousand USD | -96.21% |
| 2009 Q1 | 6.51 Million USD | 8.17% |
| 2008 Q3 | 5.56 Million USD | -45.11% |
| 2008 FY | 8.32 Million USD | -17.96% |
| 2008 Q4 | 6.02 Million USD | 8.13% |
| 2008 Q1 | 9.27 Million USD | 28.35% |
| 2008 Q2 | 10.14 Million USD | 9.38% |
| 2007 FY | 10.14 Million USD | 3.04% |
| 2007 Q1 | 8.03 Million USD | 107.97% |
| 2007 Q3 | 8.02 Million USD | -18.47% |
| 2007 Q4 | 7.22 Million USD | -9.98% |
| 2007 Q2 | 9.84 Million USD | 22.63% |
| 2006 Q4 | 3.86 Million USD | 306.65% |
| 2006 Q3 | -1.86 Million USD | -124.76% |
| 2006 Q2 | 7.54 Million USD | 231.27% |
| 2006 FY | 9.84 Million USD | 30.49% |
| 2006 Q1 | 2.27 Million USD | 4660.22% |
| 2005 Q4 | 47.86 Thousand USD | -98.67% |
| 2005 Q3 | 3.59 Million USD | -39.3% |
| 2005 Q2 | 5.92 Million USD | 52.8% |
| 2005 Q1 | 3.87 Million USD | 297.66% |
| 2005 FY | 7.54 Million USD | 27.37% |
| 2004 FY | 5.92 Million USD | 853.44% |
| 2004 Q3 | -5.55 Million USD | -606.92% |
| 2004 Q2 | -786.46 Thousand USD | 51.46% |
| 2004 Q1 | -1.62 Million USD | 32.02% |
| 2004 Q4 | -1.96 Million USD | 64.71% |
| 2003 Q1 | -2.14 Million USD | 4.58% |
| 2003 FY | -786.46 Thousand USD | -19.24% |
| 2003 Q4 | -2.38 Million USD | 83.39% |
| 2003 Q3 | -14.35 Million USD | -2075.81% |
| 2003 Q2 | -659.55 Thousand USD | 69.24% |
| 2002 Q4 | -2.24 Million USD | -88.43% |
| 2002 Q1 | -2.81 Million USD | -148.16% |
| 2002 FY | -659.55 Thousand USD | 13.5% |
| 2002 Q2 | -762.46 Thousand USD | 72.96% |
| 2002 Q3 | -1.19 Million USD | -56.38% |
| 2001 Q4 | -1.13 Million USD | 75.28% |
| 2001 FY | -762.46 Thousand USD | 57.87% |
| 2001 Q1 | -10.08 Million USD | -462.21% |
| 2001 Q2 | -1.8 Million USD | 82.06% |
| 2001 Q3 | -4.59 Million USD | -153.87% |
| 2000 Q4 | -1.79 Million USD | 84.96% |
| 2000 Q2 | -33.98 Million USD | -708.54% |
| 2000 Q3 | -11.93 Million USD | 64.9% |
| 2000 Q1 | -4.2 Million USD | -2995.17% |
| 2000 FY | -1.8 Million USD | 94.67% |
| 1999 Q1 | -331.45 Thousand USD | 27.27% |
| 1999 Q3 | -468.36 Thousand USD | 46.88% |
| 1999 FY | -33.98 Million USD | -3755.16% |
| 1999 Q4 | -135.81 Thousand USD | 71.0% |
| 1999 Q2 | -881.66 Thousand USD | -166.0% |
| 1998 FY | -881.66 Thousand USD | 1.21% |
| 1998 Q4 | -455.72 Thousand USD | 51.98% |
| 1998 Q1 | -1.61 Million USD | -43.73% |
| 1998 Q2 | -892.48 Thousand USD | 44.77% |
| 1998 Q3 | -949.12 Thousand USD | -6.35% |
| 1997 Q3 | -1.94 Million USD | 0.0% |
| 1997 FY | -892.48 Thousand USD | 31.67% |
| 1997 Q4 | -1.12 Million USD | 42.16% |
| 1996 FY | -1.3 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.09 Million CAD | 201.812% |
| Eupraxia Pharmaceuticals Inc. | -11.72 Million CAD | 29.73% |
| Helix BioPharma Corp. | -1.08 Million CAD | -661.98% |
| Microbix Biosystems Inc. | -4.96 Million CAD | -66.03% |
| Medicenna Therapeutics Corp. | -16.98 Million CAD | 51.496% |
| Satellos Bioscience Inc. | -22.06 Million CAD | 62.673% |
| Oncolytics Biotech Inc. | -31.11 Million CAD | 73.524% |
| Sernova Corp. | -8.58 Million CAD | 4.062% |